Upamostat Hydrogen Sulphate

硫酸氢乌莫司他

Report date: 2025/03/26 15:47:41
NME

Base Information

Drug NameUpamostat Hydrogen Sulphate
Drug Alias Name乌帕司他乌莫司他MesupronWX-671LH-011 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUrokinase plasminogen activator inhibitorsVirus internalization inhibitorsVirus replication inhibitors +[4] 
TargetsUrokinase plasminogen activator
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWilex AG
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesKukbo Co LtdRedhill Biopharma LtdLink Health Group +[4] 
Inactive CompaniesHeidelberg Pharma AG
Active IndicationsCoronavirus Disease 2019 (COVID-19)Pancreatic Neoplasms
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeN/A
Related LinksN/A